Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines.

Abstract

BACKGROUND:

Some men treated with atrasentan (ABT-627), an endothelin A (ETA) receptor inhibitor, had declines in their serum PSA levels. It is our hypothesis that this decrease is due to anti-tumoral activity and not a reduction in PSA secretion at the cellular level.

METHODS:

Two PSA secreting prostate cancer cell lines (LAPC4 and LNCaP) were treated with atrasentan and an ETB receptor antagonist (A192621) in varying concentrations (10(-6)-10(-10) M) and PSA levels were measured in the culture media.

RESULTS:

LNCaP and LAPC4 cells both express ETA receptors. Neither the ETA or ETB antagonist altered PSA secretion, while addition of DHT, a positive control, produced a marked increase in PSA secretion.

CONCLUSIONS:

Blockade of the ETA receptor does not affect the secretion of PSA in prostate cancer cell lines.

• Authors: Stefana Pecher, Beth R Pflug, Alisa K W Brink, Joel B Nelson
• Journal: The Prostate (Prostate) Vol. 60 Issue 3 Pg. 175-7 (Aug 01 2004) ISSN: 0270-4137 [Print] United States
• PMID: 15176046 (Publication Type: Journal Article)
• Copyright: Copyright 2004 Wiley-Liss, Inc.

Chemical References

• A 192621
• Endothelin A Receptor Antagonists
• Endothelin-1
• Pyrrolidines
• Receptor, Endothelin A
• Prostate-Specific Antigen
• Atrasentan

Topics

• Atrasentan
• Endothelin A Receptor Antagonists
• Endothelin-1 (antagonists & inhibitors)
• Humans
• Male
• Prostate-Specific Antigen (metabolism)
• Prostatic Neoplasms (pathology)
• Pyrrolidines (pharmacology)
• Receptor, Endothelin A (physiology)
• Tumor Cells, Cultured